Dayco John, Ataya Taha, Tidwell Chad, Awadelkarim Abdalaziz M, Alhusain Rashid, Ali Mohammed, Halboni Adnan, Dawdy John, Lieberman Randy
Internal Medicine, Wayne State University Detroit Medical Center, Detroit, USA.
Cureus. 2022 Apr 4;14(4):e23828. doi: 10.7759/cureus.23828. eCollection 2022 Apr.
Certain clinical scenarios should alert a physician to take a deeper look into causative pathological processes. This was evident in the case of a 41-year-old man who presented for recurrent micro thromboembolic strokes, which is atypical for the patient's age. Our desire to explain the pathological process led to the rare finding of a plasminogen activator inhibitor-1 polymorphism, which has been associated with an increased risk of cerebrovascular thrombosis. A defect in this pathway leads to the inhibition of the tissue plasminogen activator protein. This genetic polymorphism has relatively been unexplored in recent medical literature, and we are hoping that our case may inspire future research that could help potential targets of risk factor stratifications as well as the development of novel pharmacological options.
某些临床情况应提醒医生更深入地研究致病的病理过程。这在一名41岁男性患者的病例中很明显，该患者因反复发生微血栓栓塞性中风前来就诊，这在其这个年龄并不常见。我们想要解释病理过程的愿望导致了一个罕见的发现，即纤溶酶原激活物抑制剂-1多态性，它与脑血管血栓形成风险增加有关。该途径中的缺陷会导致组织纤溶酶原激活蛋白受到抑制。这种基因多态性在最近的医学文献中相对未被探索，我们希望我们的病例能激发未来的研究，这可能有助于确定风险因素分层的潜在靶点以及开发新的药物选择。
